ClinicalTrials.gg
Active, not recruitingNCT02893397Updated Sep 29, 2026

Supervised Exercise in Improving Physical Fitness Before Surgery in Patients With Resectable Bone Cancer

An interventional study of Activity Monitor and Exercise Intervention in Malignant Bone Neoplasm, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 2 sites in United States. Open to participants aged 5 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Supportive care

How we know

Updated Sep 29, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
5 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Bone Neoplasms by M.D. Anderson Cancer Center — 3 open to participants now, 6 under way, none of them phase 3. Bone Neoplasms · M.D. Anderson Cancer Center.

Started
2016
the only one that year
No phase
2 of 10
none open now
Registered
4th of 10
by date

Among the 10 studies in Bone Neoplasms by M.D. Anderson Cancer Center, this one is the only one that started in 2016, is one of 2 with no phase, and was the 4th registered.

Bone Neoplasms

259 studies on the registry are indexed under Bone Neoplasms; 70 are open to participants now.

Browse Bone Neoplasms studies →

Open to participants now

3 of the 10 studies in Bone Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 54 Bone Neoplasms studies recruiting now, 35 (65%) set no upper age limit and 13 (24%) stop at 75 or younger; 25 take children under 18; 4 take healthy volunteers.

This study: 5 Years to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Bone Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This clinical trial studies how well supervised exercise works in improving physical fitness before surgery in patients with bone cancer that can be removed by surgery. Supervised exercise may provide better short-term physical fitness in patients with bone cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine if regular exercise, which may improve delivery and efficacy of chemotherapy, is feasible in children and young adults with malignant bone tumors undergoing neoadjuvant chemotherapy.

SECONDARY OBJECTIVES:

I. To determine if exercise results in a change in tumor vascularity as evidenced by magnetic resonance imaging (MRI) in children and young adults with malignant bone tumors who participate in structured aerobic exercise as compared to children and young adults who do not.

II. To determine whether serum levels of thrombospondin-1, an endogenous anti-angiogenic protein, and sphingosine-1-phosphate, an angiogenic modulator, increase in children and young adults with malignant bone tumors who participate in supervised aerobic exercise over a 4 week period of time during neoadjuvant chemotherapy.

III. To determine if aerobic exercise decreases reactive oxygen species (ROS) in the peripheral blood of bone sarcoma patients.

IV. To determine if the numbers of circulating tumor cells decrease in patients who participate in supervised exercise over a 4 week period of time.

V. To determine whether a home-based exercise program or supervised exercise program is more feasible for this patient population.

OUTLINE: Patients are assigned to 1 of 2 groups.

GROUP I: Patients wear a fitbit and undergo supervised physical therapy exercise sessions over 40 minutes 3-5 times a week for at least 4 weeks.

GROUP II: Patients wear a fitbit.

03

Conditions studied

  • Malignant Bone Neoplasm

Browse trials for

04

Who can participate

Ages eligible
5 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have a new diagnosis of primary bone tumor, and whose treatment plan includes surgery
  • Patients who are expected to receive at least 4 weeks of chemotherapy treatment between enrollment in the study and planned surgery
  • Participants willing to wear a Fitbit

Exclusion criteria

Exclusion Criteria:

  • Patients who are not receiving their primary cancer care (surgery and chemotherapy) at MD Anderson Cancer Center (participants from the supervised exercise group only)
  • Patients who have a cognitive disorder which impacts the ability to follow directions or adhere to safety rules; this will be determined by the physical therapist by assessing whether a neurological disorder or musculoskeletal disorder would prevent the patient from safely exercising
  • Patients who have a neurological or structural disorder which would impact use of exercise equipment; this will be determined by the physical therapist by assessing whether a neurological disorder or musculoskeletal disorder would prevent the patient from safely exercising
  • Any patient who, in the opinion of the investigators, will be unable to comply with a supervised exercise regimen
  • Any concurrent co-morbid illness and/or infection which in the opinion of the investigators could make the patient unable to comply fully with the trial procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Group I (supervised exercise)

    Patients wear a fitbit and undergo supervised physical therapy exercise sessions over 40 minutes 3-5 times a week for at least 4 weeks.

    Behavioral: Exercise Intervention

  • Experimental
    Group II (fitbit)

    Patients wear a fitbit.

    Device: Activity Monitor

Interventions

  • DeviceActivity Monitor

    Wear a fitbit

    Also known as: Activity Tracker, Activity Tracker Device, Physical Activity Measuring Device

  • BehavioralExercise Intervention

    Undergo supervised exercise sessions

06

What researchers measure

Primary outcomes

  1. Feasibility defined as at least 10 of out 15 patients in the supervised exercise group complete more than or equal to 75% (9 of 12 sessions) supervised physical therapy exercise sessions

    Completion of daily exercise is defined as at least 20 minutes of aerobic exercise achieved within heart rate and blood pressure that the licensed physical therapist has determined is safe for the patient on that given day.

    Time frame: At least 4 weeks

Secondary outcomes

  1. Change in tumor vascularity as measured by magnetic resonance imaging diffusion studies

    Will use a two-sided t-test with a significance level of 5% to compare the tumor vascularity between groups.

    Time frame: Baseline up to 4 weeks

  2. Change in tumor vascularity as measured by blood serum analysis of serum thrombospondin-1 and sphingosine-1-phosphate

    Will use a two-sided t-test with a significance level of 5% to compare the tumor vascularity between groups.

    Time frame: Baseline up to 4 weeks

07

Study locations

2 sites
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2016 (actual). Primary completion is estimated for Mar 2030, 162 months after the start.

Of 36 non-industry interventional studies with no phase under Bone Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's planned 162 months is above that.

Counting every sponsor, half of 42 studies reached it within 50 months; a quarter within 14 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Aug 2026 → Mar 2030 and completion Aug 2026 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2016
First posted
Sep 8, 2016
StartActual
Aug 30, 2016
Primary completionEst.
Mar 1, 2030was Aug 2026
CompletionEst.
Mar 1, 2030was Aug 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 30, 2026→Mar 1, 2030
Sep 29, 2026
Study completion
Aug 30, 2026→Mar 1, 2030
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Primary completion Aug 30, 2026→Mar 1, 2030
    Study completion Aug 30, 2026→Mar 1, 2030

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02893397
Responsible party
Sponsor
First posted
Sep 8, 2016
Start date
Aug 30, 2016
Primary completion
Mar 1, 2030 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Sep 29, 2026

Study contacts

Valerae O Lewis
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion